Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Smolen

Showing results (81-90 of 863) with videos related to

Pageof 87
Sort By:
Reumatologia Clinica|November 18, 2011
Treating rheumatoid arthritis to target: evidence-based recommendations for enhanced disease managementMonika Schoels, Josef S Smolen
Annals of the Rheumatic Diseases|August 4, 2017
Back to the future: forget ultrasound and focus on clinical assessment in rheumatoid arthritis managementRoberto Caporali, Josef S Smolen
Current Rheumatology Reports|November 12, 2003
Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeuticsDaniel Aletaha, Josef S Smolen
Arthritis and Rheumatism|April 16, 2002
Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: clinical evaluation and cost analysisDaniel Aletaha, Josef S Smolen
Rheumatic Diseases Clinics of North America|December 8, 2009
The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical careDaniel Aletaha, Josef S Smolen
Rheumatology (Oxford, England)|September 23, 2000
Efficacy and safety of leflunomide in active rheumatoid arthritisJ S Smolen, P Emery
Zeitschrift Fur Rheumatologie|December 20, 2002
[Novel autoantibodies for the diagnosis of rheumatoid arthritis]G Steiner, J S Smolen
Arthritis Research & Therapy|January 30, 2008
The role of tumor necrosis factor-alpha in systemic lupus erythematosusMartin Aringer, Josef S Smolen
Current Opinion in Rheumatology|June 3, 1998
Are autoantibodies active players or epiphenomena?J S Smolen, G Steiner
Arthritis Research & Therapy|June 26, 2003
SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosusMartin Aringer, Josef S Smolen
Pageof 87

Showing results (81-90 of 863) with videos related to

Sort By:
Pageof 87
Reumatologia Clinica|November 18, 2011
Treating rheumatoid arthritis to target: evidence-based recommendations for enhanced disease managementMonika Schoels, Josef S Smolen
Annals of the Rheumatic Diseases|August 4, 2017
Back to the future: forget ultrasound and focus on clinical assessment in rheumatoid arthritis managementRoberto Caporali, Josef S Smolen
Current Rheumatology Reports|November 12, 2003
Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeuticsDaniel Aletaha, Josef S Smolen
Arthritis and Rheumatism|April 16, 2002
Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: clinical evaluation and cost analysisDaniel Aletaha, Josef S Smolen
Rheumatic Diseases Clinics of North America|December 8, 2009
The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical careDaniel Aletaha, Josef S Smolen
Rheumatology (Oxford, England)|September 23, 2000
Efficacy and safety of leflunomide in active rheumatoid arthritisJ S Smolen, P Emery
Zeitschrift Fur Rheumatologie|December 20, 2002
[Novel autoantibodies for the diagnosis of rheumatoid arthritis]G Steiner, J S Smolen
Arthritis Research & Therapy|January 30, 2008
The role of tumor necrosis factor-alpha in systemic lupus erythematosusMartin Aringer, Josef S Smolen
Current Opinion in Rheumatology|June 3, 1998
Are autoantibodies active players or epiphenomena?J S Smolen, G Steiner
Arthritis Research & Therapy|June 26, 2003
SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosusMartin Aringer, Josef S Smolen
Pageof 87